GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (NAS:ZVRA) » Definitions » Degree of Operating Leverage

ZVRA (Zevra Therapeutics) Degree of Operating Leverage : 0.88 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Zevra Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was 0.88. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Zevra Therapeutics's Degree of Operating Leverage or its related term are showing as below:

ZVRA's Degree of Operating Leverage is ranked worse than
66.52% of 887 companies
in the Biotechnology industry
Industry Median: -0.02 vs ZVRA: 0.88

Zevra Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for Zevra Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics Degree of Operating Leverage Chart

Zevra Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.69 0.39 -3.49 0.40 -6.12

Zevra Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 7.06 7.23 -6.12 0.88

Competitive Comparison of Zevra Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, Zevra Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zevra Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Zevra Therapeutics's Degree of Operating Leverage falls into.


;
;

Zevra Therapeutics Degree of Operating Leverage Calculation

Zevra Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -66.78 (Mar. 2025) / -47.367 (Mar. 2024) - 1 )/( 40.588 (Mar. 2025) / 27.71 (Mar. 2024) - 1 )
=0.4098/0.4647
=0.88***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Zevra Therapeutics  (NAS:ZVRA) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Zevra Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Zevra Therapeutics Business Description

Traded in Other Exchanges
Address
1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Executives
Watton Corey Michael director 22045 KAREN STREET, ELKHORN NE 68022
John B Bode director C/O TRIBUNE PUBLISHING COMPANY, 202 W. FIRST STREET, LOS ANGELES CA 90012
Neil F. Mcfarlane director, officer: President and CEO C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
R. Laduane Clifton officer: VP Fin & Corp Controller C/O KEMPHARM, INC., 1170 CELEBRATION BLVD., #103, CELEBRATION FL 34747
Joshua Schafer officer: CCO & EVP, Bus. Development SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Timothy J. Sangiovanni officer: VP, Corporate Controller C/O KEMPHARM, INC., 2500 CROSSPARK RD, STE E-126, CORALVILLE IA 52241
Thomas Anderson director 215 FIRST STREET, CAMBRIDGE MA 02142
Douglas W Calder director 324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Wendy L Dixon director
Tamara A Seymour director C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Matthew R Plooster director 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Richard W Pascoe director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Christopher Posner director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Travis C Mickle director, 10 percent owner, officer: President & CEO 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241